|
Zapomeran
Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-based COVID-19 vaccine.[1] It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein.[1] Self-amplifying means that the mRNA also carries instructions to make a protein called replicase.[1] Kostaive was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved.[2][3] Medical usesZapomeran is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus.[1] Society and cultureLegal statusKostaive was approved for medical use in Japan in November 2023.[4][5][6] In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults.[1] The applicant for this medicinal product is Arcturus Therapeutics Europe B.V.[1] NamesZapomeran is the international nonproprietary name.[7][8] References
Further reading
|
||||||||||||||||||||||||||||
.svg){kind=small}
